Farnesoid x receptor agonist for the treatment of liver and metabolic disorders: Focus on 6-ethyl-CDCA

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 753-762

  Fiorucci, S ^a   Cipriani, S ^a   Mencarelli, A ^a   Baldelli, F ^a   Bifulco, G ^b   Zampella, A ^c  

^a Nuova Facoltà di Medicina   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chenodeoxycholic acid; Cholestasis; FXR; MRP4; Non alcoholic liver steatosis (NASH)

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; AGN 31; AGN 34; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; CHOLESTEROL; FARNESOID X RECEPTOR; FATTY ACID; FEXERAMINE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; LITHOCHOLIC ACID; OBETICHOLIC ACID; PIOGLITAZONE; ROSIGLITAZONE; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA HELIX; ANTIINFLAMMATORY ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BILE ACID METABOLISM; BILE DUCT FISTULA; DIABETES MELLITUS; DISEASE EXACERBATION; DOWN REGULATION; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FATTY LIVER; HUMAN; INSULIN SENSITIVITY; INSULIN TREATMENT; INTRAHEPATIC CHOLESTASIS; LIGAND BINDING; LIPID METABOLISM; LIVER DISEASE; LIVER FIBROSIS; METABOLIC DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY BILIARY CIRRHOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STEADY STATE; UPPER ABDOMINAL PAIN; UPREGULATION;

ANIMALS; CHENODEOXYCHOLIC ACID; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOGLYCEMIC AGENTS; LIVER DISEASES; METABOLIC DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79960617989     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711796355258     Document Type: Review

References (63)

1. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan B. Identification of a nuclear receptor for bile acids. Science, 1999, 284, 1362-1365.
2. Modica, S.; Bellafante, E.; Moschetta, A. Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. Front. Biosc., 2009, 14, 4719-4745.
3. Fiorucci, S.; Baldelli, F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol., 2009, 25, 252-259.
4. Trauner, M.; Fickert, P.; Halilbasic, E.; Moustafa, T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien. Med. Wochenschr., 2008, 158, 542-548.
5. Fiorucci, S.; Rizzo, G.; Donini, A.; Distrutti, E.; Santucci, L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med., 2007, 13, 298-309.
6. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Palladino, G.; Cipriani, S. Targeting farnesoid-X-receptor: From medicinal chemistry to disease treatment. Curr. Med. Chem., 2010, 17, 139-159.
7. Cipriani, S.; Mencarelli, A.; Palladino, G.; Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Jour. Lip. Res., 2010, 51, 771-784.
8. Fiorucci, S.; Mencarelli, A.; Palladino, G.; Cipriani, S. Bile-acidactivated receptors: Targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders Trends Pharmacol. Sci., 2009, 30, 570-580.
9. Nguyen, A.; Bouscarel, B. Bile acids and signal transduction: Role in glucose homeostasis Cell Signal., 2008, 20, 2180-2197.
10. Malerod, L.; Sporstol, M.; Juvet, L.K.; Mousavi, S.A.; Gjoen, T.; Berg, T.; Roos, N.; Eskild, W. Bile acids reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR, SHP, and LRH- 1. Biochem. Biophys. Res Commun., 2005, 336,1096-1105.
11. Zollner, G.; Marschall, H.U.; Wagner, M.; Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations Mol. Pharmacol., 2006, 3, 231-251.
12. Jung, D.; Mangelsdorf, D.J.; Meyer, U.A. Pregnane X receptor is a target of farnesoid X receptor. J. Biol. Chem., 2006, 281, 19081-19091.
13. Renga, B.; Mencarelli, A.; Migliorati, M.; Cipriani, S.; Distrutti, E.; Fiorucci, S. SHP-dependent and -independent induction of PPARγ by the bile acid sensor FXR counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Inflamm. Res, 2011, 60, 577-87.
14. Kremer, A.E.; Beuers, U.; Oude-Elferink, R.P.J.; Pusl, T. Pathogenesis and treatment of pruritus in cholestasis. Drugs, 2008, 68, 2163-2182.
15. Honda, M.; Kawai, H.; Shirota, Y.; Yamashita, T.; Kaneko, S. Differential gene expression profiles in stage I primary biliary cirrhosis. Am. J. Gastroenterol., 2005, 100, 2019-2030.
16. Zollner, G.; Fickert, P.; Silbert, D.; Fuchsbichler, A.; Marschall, H.U.; Zatloukal, K.; Denk, H.; Trauner, M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol., 2003, 38, 717-727.
17. Lindor, K.D.; Therneau, T.M.; Jorgensen, R.A.; Malinchoc, M.; Dickson, E.R. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology, 1996, 110, 1515-1518.
18. Corpechot C.; Carrat, F.; Bahr, A.; Chretien, Y.; Poupon, R.E.; Poupon, R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology, 2005,128, 297-303.
19. Jorgensen, R.; Angulo, P.; Dickson, E.R.; Lindor, K.D. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am. J. Gastroenterol., 2002, 97, 2647-2650.
20. Poupon, R.E.; Bonnand, A.M.; Chretien, Y.; Poupon, R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology, 1999, 29,1668-1671.
21. Pares, A.; Caballeria, L.; Rodes, J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology, 2006, 130, 715-720.
22. Poupon, R.E.; Lindor, K.D.; Pares, A.; Chazouilleres, O.; Poupon, R.; Heathcote, E.J. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J. Hepatol., 2003, 39, 12-16.
23. Corpechot, C.; Carrat, F.; Bonnand, A.M.; Poupon, R.E.; Poupon, R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology, 2000, 32, 1196-1199.
24. Gong, Y.; Huang, Z.B.; Christensen, E.; Gluud, C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: An updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am. J. Gastroenterol., 2007, 102, 1799-1807.
25. Goulis, J.; Leandro, G.; Burroughs, A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis Lancet, 1999, 354, 1053-1060.
26. Gillespie, D.A.; Vickers, C.R. Pruritus and cholestasis: Therapeutic options. J. Gastroenterol. Hepatol., 1993, 8, 168-173.
27. Sepe V, Bifulco G, Renga B, D'Amore C, Fiorucci S, Zampella A. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. J. Med. Chem., 2011, 54,1314-20.
28. De Marino S, Ummarino R, D'Auria MV, Chini MG, Bifulco G, Renga B, D'Amore C, Fiorucci S, Debitus C, Zampella A. Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J. Med. Chem., 2011 Apr 5.
29. Festa C, De Marino S, D'Auria MV, Bifulco G, Renga B, Fiorucci S, Petek S, Zampella A. Solomonsterols A and B from Theonella swinhoei. The first example of c-24 and c-23 sulfated sterols from a marine source endowed with a pxr agonistic activity. J. Med. Chem., 2010 Dec 9.
30. Intercept Pharmaceuticals Inc Company World Wide Web Site, 2010, June 18.
31. Henry, R.R.; Mudaliar, S.; Morrow, L.; Hompesch, M.; Kipnes, M.; Sanyal, A.; Clopton, P.; Böhm, O.; Sciacca, C.; Mavian, A.; Pruzan-ski, M.; Shapiro, D. Farnesoid-X Receptor Agonists: A New Therapeutic Class for Diabetes and Fatty Liver Disease? The First FXR Therapeutic Study in Diabetes. Ann. Meet. A. Diabetes Assoc., 2009, 69th June 07 Abs LB-13.
32. Shapiro D.; March, B.; Eliot, L.; du Bois, R.; Pruzanski, M. First human experience with a synthetic farnesoid x receptor (FXR) agonist - INT-747 (6alpha-ethylchenodeoxycholic acid). Hepatology, 2009, 50, Suppl 770A-771.
33. Sanyal, A.J.; Mudaliar, S.; Henry, R.R.; Marschall, H.U.; Morrow, L.; Sciacca, C.I.; Dillon, P.; Clopton, P.; Kipnes, M.; Shapiro, D. A new therapy for nonalcoholic fatty liver disease and diabetes? int- 747 - the first fxr hepatic therapeutic study. Hepatology, 2009, 50, Suppl 389A-390A.
34. Mason, A.; Luketic, V.; Lindor, K.; Hirschfield, G.; Gordon, S.; Mayo, M.; Kowdley, K.; Pares, A.; Trauner, M.; Castelloe, E.; Sciaca, C.; Jones, T.B.; Bohm, O.; Shapiro, D. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholicacid. J. Hepatol., 2010, 52, S1-S2. [Poster].
35. Intercept Pharmaceuticals Inc press release, 2010, July 28.
36. Intercept Pharmaceuticals Inc Int. Biotechonol. Conv. & Exhib., 2010, May 06.
37. Pellicciari, R.; Costantino, G.; Camaioni, E.; Sadeghpour, B.M.; Entrena, A.; Willson, T.M.; Fiorucci, S.; Clerici, C.; Gioiello, A. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J. Med. Chem., 2004, 47, 4559-4569.
38. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P.R.; Morelli, A.; Parks, D.J.; Willson, T.M. 6alphaethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem., 2002, 45, 3569-3572.
39. Pellicciari, R.; Costantino, G.; Fiorucci, S. Farnesoid X Receptor: From structure to potential clinical applications. J. Med. Chem., 2005, 48, 5383-5403.
40. Downes, M.; Verdecia, M.A.; Roecker, A.J.; Hughes, R.; Hogenesch, J.B.; Kast-Woelbern, H.R.; Bowman, M.E.; Ferrer, J.L.; Anisfeld, A.M.; Edwards, P.A.; Rosenfeld, J.M.; Alvarez, J.G.; Noel, J.P.; Nicolaou, K.C.; Ecans, R.M. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell, 2003, 11, 1079-1092.
41. Pellicciari, R.; Gioiello, A.; Costantino, G.; Sadeghpour, B.M.; Rizzo, G.; Meyer, U.; Parks, D.J.; Entrena-Guadix, A.; Fiorucci, S. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. J. Med. Chem., 2006, 49, 4208-4215.
42. Mi, L.Z.; Devarakonda, S.; Harp, J.M.; Han, C.; Pellicciari, R.; Willson, T.M.; Khorasanizadeh, S.; Rastinejad, F. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell, 2003, 11, 1093-1100.
43. Rizzo, G.; Disante, M.; Renga, B.; Pruzanski, M.; Pellicciari, R.; Fiorucci, S. The fanesoid-x-receptor ligand int-747 regulates organic transporters alpha and beta (ost alpha and ost beta) in liver cells and rodent model of cholestasis. Gastroenterology, 2006, 130, A815.
44. Fiorucci, S.; Clerici, C.; Castellani, D.; Sabatino, G.; Antonelli, E.; Goodwin, B.; Willson, T.M.; Setchell, K.D.; Morelli, A.; Pellicciari, R. The fxr-agonist, 6-ethyl-chenodeoxycholic acid (6-ECDCA), protects against estrogen-induced cholestasis in rats. Gastroenterology, 2003, 124, 4 A698.
45. Fiorucci, S.; Clerici, C.; Antonelli, E.; Orlandi, S.; Goodwin, B.; Sadeghpour, B.M.; Sabatino, G.; Russo, G.; Castellani, D.; Willson, T.M.; Pruzanski, M.; Pellicciari, R.; Morelli, A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther., 2005, 313, 604-612.
46. [Fiiorucci, S.; Clerici, C.; Antonelli, E.; Morelli, A.; Pellicciari, R. A novel and potent FXR agonist inhibits endogenous bile acids synthesis and protects against cholestasis. Gastroenterology, 2002, 122, 4 A-444.
47. Rizzo, G.; Disante, M.; Mencarelli, A.; Renga, B.; Gioiello, A.; Pellicciari, R.; Fiorucci, S. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol., 2006, 70, 1164-1173.
48. Renga, B.; Mencarelli, A.; Valvassori, P.; Brancaleone, V.; Fiorucci, S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta Mol. Basis Dis., 2010, 1802, 363-372.
49. Wang, X.X.; Jiang, T.; Shen, Y.; Adorini, L.; Pruzanski, M.; Gonzalez, F.J.; Scherzer, P.; Lewis, L.; Miyazaki-Anzai, S.; Levi, M. The farnesoid x receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am. J. Physiol. Renal Physiol., 2009, 297, F1587-F1596.
50. Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. Antiatherosclerotic effect of farnesoid x receptor. Am. J. Physiol. Heart Circulat. Physiol., 2009, 296, H272-H281.
51. Miyazaki-Anzai, S.; Levi, M.; Kratzer, A.; Ting, T.C.; Lewis, L.B.; Miyazaki, M. Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE(-/-) Mice With Chronic Kidney Disease. Circ. Res, 2010, 106, 1807-NIL-0055.
52. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Riccardi, L.; Morelli, A.; Pruzanski, M.; Pellicciari, R. Cross-talk between farnesoid-x-receptor (FXR) and peroxisome proliferatoractivated receptor gamma contributes to the antifibrotic activity of fxr ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther., 2005, 315, 58-68.
53. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Riccardi, L.; Orlandi, S.; Pruzanski, M.; Morelli, A.; Pellicciari, R. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther., 2005, 314, 584-595.
54. Albanis, E.; Alvarez, C.E.; Pruzansky, M.; Friedman, S.L.; Fiorucci, S. Int-747, a novel fxr activator, reverses hepatic fibrosis and cirrhosis in thioacetamide-induced liver injury in rats. Hepathology, 2005, 42, 605A-606A.
55. Fiorucci, S.; Antonelli, E.; Rizzo, G.; Renga, B.; Mencarelli, A.; Riccardi, L.; Orlandi, S.; Pellicciari, R.; Morelli, A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology, 2004, 127, 1497-1512.
56. Vairappan, B.; Sharma, V.; Winstanley, A.; Davies, N.; Shah, N.; Jalan, R.; Mookerjee, R.P. Modulation of the ddah-adma pathway with the farnesoid x receptor (FXR) agonist int-747 restores hepatic enos activity and lowers portal pressure in cirrhotic rats. Hepatology, 2009, 50, Suppl 336A-337A.
57. Renga, B.; Mencarelli, A.; Migliorati, M.; Distrutti, E.; Fiorucci, S. Bile-acid-activated farnesoid x receptor regulates hydrogen sulfide production and hepatic microcirculation. World. J. Gastroenterol., 2009, 15, 2097-2108.
58. Valvassori, P.; Mencarelli, A.; Renga, B.; Rizzo, G.; Morelli, A.; Pruzanski, M.; Pellicciari, R.; Fiorucci, S. An essential role of farnesoid x-receptor in regulating intestinal fibrosis in murine model of chronic colitis Gastroenterology, 2006, 130, 4 A45.
59. Fiorucci, S.; Renga, B.; Rizzo, G.; Mencarelli, A.; Disante, M.; Pruzanski, M.; Pellicciari, R.; Morelli, A. Essential counterregulatory role of farnesoid-x-receptor (FXR) for intestinal innate immunity. Gastroenterology, 2006, 130, 4 A87.
60. Vavassori, P.; Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol., 2009, 183, 6251-6261.
61. Renga, B.; Migliorati, M.; Mencarelli, A.; Cipriani, S.; D'Amore, C.; Distrutti, E.; Fiorucci, S. The Farnesoid X Receptor suppresses Constitutive Androstane Receptor activity at the Multidrug Resistance Protein-4 promoter. Biochim. Biophys. Acta. 2011 1809: 157-65.
62. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 79-104.
63. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A.; Van Natta, M.; Clark, J.; Brunt, E.M.; Kleiner, D.E.; Hoofnagle, J.H.; Robuck, P.R.; NASH, C.R.N. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 2010, 362, 1675-1685.